Key result
Urine AcSDKP measurement by LC-MS/MS is a reliable marker of ACE inhibitor intake, demonstrating 92.2% sensitivity and 100% specificity for adherence assessment.
Why the study?
Chemical adherence testing by LC-MS/MS is limited by the large number of drugs to detect, prompting validation of urine AcSDKP measurement compared to active ACEI metabolites.
Does urine AcSDKP measurement accurately detect nonadherence to ACE inhibitors compared to active ACEI metabolites in hypertensive outpatients?
Cohort
Does urine AcSDKP measurement accurately detect nonadherence to ACE inhibitors compared to active ACEI metabolites in hypertensive outpatients?
Absolute Event Rate: 79% vs 85.7%
Spot urine AcSDKP measurement by LC-MS/MS is a highly sensitive and specific biomarker for assessing adherence to ACEI treatment in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Supports AcSDKP LC-MS/MS for ACEI adherence monitoring in outpatients; leaves open prospective validation before clinical adoption.
A 2021 study conducted a cohort in hypertension. Urine AcSDKP measurement vs. ACEI active metabolites was evaluated on Evaluation of good adherence. Urine AcSDKP measurement by LC-MS/MS is a reliable marker of ACE inhibitor intake, demonstrating 92.2% sensitivity and 100% specificity for adherence assessment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: